SCHEMBL4479532

SCHEMBL4479532

N#Cc1c(Nc2ccc(C(=O)NC3CCOC3=O)cc2)sc(C(=O)c2ccc(-c3ccccn3)s2)c1N

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.46
ALDH1A1 P00352 4/20 0.46
GAA P10253 1/20 0.46
HPGD P15428 2/20 0.45
MAPK1 P28482 2/20 0.45
HTT P42858 1/20 0.45
POLB P06746 2/20 0.43
LMNA P02545 2/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
ALOX12 P18054 1/20 0.43
MELK Q14680 5/20 0.40
MAPK11 Q15759 1/20 0.39
MAPK14 Q16539 1/20 0.39
CHRNA7 P36544 2/20 0.37
RAB9A P51151 2/20 0.37
HDAC3 O15379 1/20 0.35
HDAC4 P56524 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC7 Q8WUI4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4471831 0.88 MAPT (0.48) MAPTALDH1A1GAAHPGDMAPK1
SCHEMBL4469448 0.86 MELK (0.45) MAPTALDH1A1GAAHPGDMAPK1
SCHEMBL4468052 0.81 MAPT (0.48) MAPTALDH1A1GAAHPGDMAPK1
SCHEMBL4472094 0.81 MAPT (0.51) MAPTALDH1A1GAAHPGDMAPK1
SCHEMBL4464981 0.81 MAPT (0.47) MAPTALDH1A1GAAHPGDMAPK1
SCHEMBL4476805 0.79 MAPT (0.46) MAPTALDH1A1GAAHPGDMAPK1
SCHEMBL4474220 0.79 MAPT (0.46) MAPTALDH1A1GAAHPGDMAPK1
SCHEMBL4470254 0.78 ALDH1A1 (0.54) MAPTALDH1A1GAAHPGDMAPK1
SCHEMBL4477182 0.78 MAPT (0.51) MAPTALDH1A1GAAHPGDMAPK1
SCHEMBL4484012 0.78 ALDH1A1 (0.56) MAPTALDH1A1GAAHPGDMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 US disclosed
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 US disclosed
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 US disclosed
US-20060041006-A1 PDE4B inhibitors and uses therefor PLEXXIKON, INC. 2006-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PDE4B, PDE7B, PDE4A MAPT 3524/4885ALDH1A1 802/4885GAA 77/4885
US-20060041006-A1 PDE4B inhibitors and uses therefor PDE4B, PDE7B, PDE4A MAPT 3524/4885ALDH1A1 802/4885GAA 77/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.